Pfizer [NYSE: PFE] and Merck Award License to its Firms to Produce COVID-19 Pills

Pfizer Inc. [NYSE: PFE] and Merck & Co., Inc. [NYSE: MRK] disclosed that they have awarded a license to firms in Vietnam to manufacture COVID-19 treatment pills. Vietnam ministry disclosed that five local pharmaceutical companies have shown their intent to purchase the license for manufacturing Molnupiravir.

The companies have delivered letters of authorization to the Drug Administration of Vietnam for the manufacturing of Molnupiravir and Paxlovid pills. Vietnam has so far logged 1.1 million COVID-19 infections and 24,000 people succumbed to COVID-19. Furthermore, more than 47% of its population of 98 million have been fully vaccinated against coronavirus.

Additionally, the ministry of Vietnam disclosed that Vietnam has so far used 250,000 Molnupiravir doses, with 72%-93% of recipients improving after five days. Moreover, Pfizer has revealed earlier that it would enable generic producers to deliver its experimental antiviral COVID-19 pill to 95 low- and middle-income countries through a voluntary licensing agreement with international public health group Medicines Patent Pool (MPP).

Previously, Pfizer Inc sent an invitation to investors and the general public to view and listen to a webcast of a discussion with Bob Smith, VP, Pfizer Rare Disease. The 4th Annual Evercore ISI HealthCONx Conference is scheduled to hold on Wednesday, December 1, 2021, at 5:10 p.m. Eastern Standard Time.